Related Experiment Video

Updated: Jan 20, 2026

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
12:34

Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment

Published on: January 12, 2024

1.2K

A dataset describing a suite of novel antibody reagents for the RAS signaling network

Regine M Schoenherr1, Dongqing Huang1, Uliana J Voytovich1

  • 1Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Scientific Data
|August 31, 2019
PubMed

Insights

Researchers developed 104 novel monoclonal antibodies (mAbs) to detect RAS network proteins. These validated reagents aid in quantifying phosphopeptides and unmodified peptides, advancing cancer research and therapeutic development for RAS-driven cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • RAS genes are frequently mutated in various cancers, posing significant therapeutic challenges.
  • Effective therapies for RAS-driven cancers have been limited due to difficulties in targeting these proteins.
  • Understanding RAS signaling pathways is crucial for developing novel cancer treatments.

Purpose of the Study:

  • To develop and validate novel reagents for quantifying RAS network proteins.
  • To create a comprehensive dataset of monoclonal antibodies (mAbs) for RAS protein detection.
  • To support research efforts focused on RAS-driven cancers and therapeutic strategies.

Main Methods:

  • Development and validation of 104 monoclonal antibodies (mAbs).
  • Antibodies target 27 phosphopeptides and 69 unmodified peptides from 20 RAS network proteins.
  • Characterization of antibody utility in Western blotting, immunoprecipitation, protein arrays, immunohistochemistry, and targeted mass spectrometry.

Main Results:

  • A dataset of 104 validated monoclonal antibodies (mAbs) for RAS network protein detection is presented.
  • Antibodies enable quantification of specific phosphopeptides and unmodified peptides across multiple applications.
  • Characterization data confirms antibody utility in diverse experimental settings.

Conclusions:

  • The developed reagents provide essential tools for researchers studying RAS signaling pathways.
  • Publicly available antibodies and data facilitate the measurement of expression changes in RAS networks.
  • These resources will advance the understanding and treatment of RAS-driven cancers.

More Related Videos

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

1.1K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.4K

Related Concept Videos

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology12:34

The Efficacy and Underlying Pathway Mechanisms of ShiDuGao Treatment for Anus Eczema Based on GEO Datasets and Network Pharmacology

This investigative effort sought to elucidate the mechanism of topical drug administration using a synergistic integration of network pharmacology and gene expression omnibus (GEO) datasets. This article evaluated the feasibility, target, and mechanism of ShiDuGao (SDG) in treating anus eczema.
1.2K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.1K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

The use of cytokine release assay reference reagents allows for more reproducible and standardized in vitro safety profiles of immunotherapeutic monoclonal antibodies. Here we describe how cytokine release assays can be used alongside a reference reagent panel to predict the safety of some therapeutic monoclonal...
1.1K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

The genetically tractable nematode Caenorhabditis elegans can be used as a simple and inexpensive model for drug discovery. Described here is a protocol to identify anticancer therapeutics that inhibit the downstream signaling of RAS and EGFR...
3.4K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
5.2K
Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Here, we present a protocol for antibody arrays to identify alterations in signaling pathways in various cellular models. These changes, caused by drugs/hypoxia/ultra-violet light/radiation, or by overexpression/downregulation/knockouts, are important for various disease models and can indicate whether a therapy will be effective or can identify mechanisms of drugs...
8.3K